OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) saw a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 83,450 shares, a decline of 38.4% from the July 30th total of 135,370 shares. Based on an average daily trading volume, of 69,382 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.3% of the shares of the company are short sold.
Analyst Ratings Changes
A number of brokerages have recently issued reports on OKYO. Weiss Ratings restated a "sell (d-)" rating on shares of OKYO Pharma in a research report on Friday, July 17th. HC Wainwright reduced their target price on shares of OKYO Pharma from $7.00 to $5.00 and set a "buy" rating for the company in a report on Monday, July 13th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $5.67.
Get Our Latest Stock Analysis on OKYO Pharma
OKYO Pharma Price Performance
Shares of OKYO Pharma stock opened at $1.67 on Monday. The company's fifty day simple moving average is $1.56 and its two-hundred day simple moving average is $1.61. OKYO Pharma has a 12-month low of $1.34 and a 12-month high of $3.20.
Hedge Funds Weigh In On OKYO Pharma
Hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in OKYO Pharma in the third quarter worth about $31,000. Renaissance Technologies LLC boosted its position in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company's stock valued at $286,000 after acquiring an additional 96,800 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of OKYO Pharma during the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 2.97% of the company's stock.
About OKYO Pharma
(
Get Free Report)
Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.
Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
